<DOC>
	<DOCNO>NCT01350635</DOCNO>
	<brief_summary>The aim present skin test study CS-BM32-001 evaluate whether BM32 proteins exhibit low/no allergenic activity apply skin prick- atopy patch test grass pollen allergic patient</brief_summary>
	<brief_title>Skin Test Study BM32</brief_title>
	<detailed_description>BM32 hypoallergenic grass pollen allergy vaccine consist aluminum hydroxide-adsorbed equimolar mix four active ingredient , BM321 , BM322 , BM325 BM326 . The four active ingredient purify recombinant protein contain non-allergenic peptide four major timothy grass pollen allergen , Phl p 1 ( BM321 ) , Phl p 2 ( BM322 ) , Phl p 5 ( BM325 ) Phl p 6 ( BM326 ) fuse PreS domain hepatitis B virus , protein use childhood vaccine . BM32 hold promise induce IgE mediate immediate type ( e.g . anaphylactic reaction ) T-cell mediate late phase side effect immunotherapy . The aim present skin test study CS-BM32-001 evaluate whether BM32 protein due low/absent IgE- T cell-reactivity exhibit low/no allergenic activity apply skin prick- atopy patch test grass pollen allergic patient ( n=60 ) . This study therefore provide important information immunotherapy study base BM32 .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Positive history grass pollen allergy positive skin prick test reaction grass pollen extract Age 18 60 year Subjects must standard health care insurance Subject must appear capable understand comply relevant aspect study protocol pregnancy breast feed autoimmune disease , immune defect include immuno suppression , immunecomplexinduced immunopathies contraindication adrenaline severe general malady , malignant diseases patient longterm treatment systemic corticosteroid , immunosuppressive drug , tranquilizer psychoactive drug contraindication skin prick testing : skin inflammation test area , urticaria facticia , unstable uncontrolled bronchial asthma ( 30 ) use betablockers participation another clinical trial within one month prior study ; however , participation previous month solely form blood donation without intervention acceptable risk noncompliance study procedure restriction use oral H1 antihistamine within previous 3 day , oral Ketotifen within previous 5 day topical corticosteroid test area within previous 14 day . systemic ( shortterm ) corticosteroid within previous 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Specific Immunotherapy</keyword>
	<keyword>Grass pollen vaccine</keyword>
	<keyword>Allergy</keyword>
	<keyword>Grass Pollen Allergy</keyword>
</DOC>